PPARA变种rs1800234对治疗奇格利塔扎尔的治疗反应产生了剂量依赖的药物遗传学影响
Zhaoxu Geng1,2, Yuanting Zheng3, Qian Li2
1Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Pharmacogenomics
|November 18, 2024
概括
PPARA基因变体rs1800234影响了2型糖尿病患者对奇格利塔扎尔的反应. 这种药物遗传学发现表明rs1800234可以指导这种药物的未来剂量策略.
科学领域:
- 药物遗传学 药物遗传学
- 基因组学就是基因组学.
- 代谢疾病 代谢疾病
背景情况:
- 药物反应的个体间变异性是临床实践中的一个重大挑战.
- 了解药物反应的遗传基础可以优化治疗结果.
- PPAR基因是代谢疾病治疗的关键标.
研究的目的:
- 研究药物向基因中的功能变异对治疗反应的药物遗传影响.
- 为了确定特定的遗传变异是否解释了患者对奇格利塔扎尔的反应的变化.
- 探索PPAR基因变异与中国2型糖尿病 (T2DM) 患者的奇格利塔萨尔疗效之间的关联.
主要方法:
- 对奇格利塔扎尔随机对照临床试验数据的后期分析.
- 481名中国T2DM患者的基因型定型.
- 线性回归分析以评估PPAR基因变异与不同剂量奇格利塔萨尔治疗结果的关联.
主要成果:
- PPARA变体rs1800234 (一种功能获取变体) 显示了对奇格利塔萨尔反应的剂量依赖性药物遗传效应.
- rs1800234的C等位基因与48毫克剂量的治疗反应减少有关,但32毫克剂量的治疗反应没有减少.
- 患者的反应因rs1800234基因型和奇格利塔萨尔剂量而异,C等位基因的携带者在较高剂量时表现出更差的反应.
结论:
- 这种PPARA变体rs1800234显著影响着奇格利塔萨尔的治疗反应,其剂量取决于剂量.
- 这种变异可能解释了观察到的奇格利塔扎尔没有明确的剂量效果关系.
- rs1800234作为优化奇格利塔萨尔剂量的潜在生物标志物,并为多向药物的开发提供信息.
更多相关视频
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
01:23Dipeptidyl Peptidase 4 Inhibitors
172
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172